Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy

Journal of Drugs in Dermatology

Volumn 8, Issue 9, 2009, Pages 873-876

  Rullan, Peter ^a   Murase, Jenny ^b  

^a Dermatology Institute Chula Vista   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZITHROMYCIN; BETAMETHASONE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CREATININE; CYCLOSPORIN; DOXEPIN; ETANERCEPT; FEXOFENADINE; FLUOCINOLONE ACETONIDE; HYDROXYZINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; SALICYLIC ACID; STEROID; TACROLIMUS; TRIAMCINOLONE; CYTOKINE; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ALLERGIC RHINITIS; ARTICLE; ATOPIC DERMATITIS; BACTERIAL SKIN DISEASE; BODY SURFACE; CASE REPORT; CHRONIC DISEASE; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HUMAN; LICHENOID ERUPTION; MALE; PRURITUS; RECURRENT DISEASE; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; CYTOKINES; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 70349314513     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53(1 Suppl 1):S86-S93. (Pubitemid 40828185)
2. Pellegrino M, Minervini B, Musto P, et al. Tumor necrosis factoralpha and interleukin-1 beta. Two possible mediators of allergic inflammation. Minerva Pediatr. 1996;48(7-8):309-312. (Pubitemid 126545184)
3. Sumimoto S, Kawai M, Kasajima Y, Hamamoto T. Increased plasma tumour necrosis factor-alpha concentration in atopic dermatitis. Arch Dis Child. 1992;67(3):277-279.
4. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factoralpha antagonists. Br J Dermatol. 2007;156(3):486-491.
5. Lebas D, Staumont-Salle D, Solau-Gervais E, et al. [Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases]. Ann Dermatol Venereol. 2007;134(4 Pt 1):337-342.
6. Mangge H, Gindl S, Kenzian H, Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2003;30(11):2506-2507. (Pubitemid 37413916)
7. Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol. 2003;49(1):160-161. (Pubitemid 36801660)
8. Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol. 2004;3(3):315-318.
9. Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2005;52(3 Pt 1):522-526.
10. Buka RL, Resh B, Roberts B, et al. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol. 2005;53(2):358-359. (Pubitemid 40979606)
11. Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol. 2006;19(1):237-240.
12. Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Invest Dermatol Symp Proc. 2007;12(1):9-15. (Pubitemid 46763029)
13. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36(3):159-167. (Pubitemid 44691882)
14. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454-467. (Pubitemid 351471762)
15. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183-3194.
16. Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128(11):2625-2630.